Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines

J Cancer Res Ther. 2023 Apr;19(Supplement):S278-S284. doi: 10.4103/jcrt.JCRT_565_19.

Abstract

Background: The poor response of metastatic osteo- and chondrosarcomas to chemotherapy could be the result of multidrug resistance (MDR), which may be overcome through the use of small interfering RNA (siRNA). However, several methodologic questions remain unresolved.

Aims: To test the toxicity of three commonly used siRNA transfection reagents and apply the least toxic reagent to investigate the siRNA-induced MDR1 mRNA knockdown.

Methods: The toxicity of TransIT-TKO, Lipofectamine 2000, and X-tremeGENE siRNA transfection reagents was investigated on osteosarcoma (MG-63) and chondrosarcoma (SW1353) cell lines. The toxicity was measured at 4 and 24 hours using a MTT toxicity assay. The least toxic transfection reagent was applied to investigate the siRNA-induced MDR1 mRNA knockdown effect using qRT-PCR. Furthermore, five housekeeping genes were assessed in the BestKeeper software to obtain mRNA expression normalization.

Results: Lipofectamine 2000 was the least toxic transfection reagent, reducing the cell viability only in chondrosarcoma 24 hours following exposure to the highest dose. In contrast, TransIT-TKO and X-tremeGENE transfection reagents displayed a significant reduction in cell viability in both chondrosarcoma after 4 hours and in osteosarcoma after 24 hours. Significant MDR1 mRNA silencing of over 80% was achieved in osteo- and chondrosarcoma using Lipofectamine at a final siRNA concentration of 25 nM. No significant dose response was observed in knockdown efficiency in either Lipofectamine or siRNA concentration.

Conclusion: Lipofectamine 2000 was the least toxic transfection reagent in osteo- and chondrosarcoma. Successful siRNA-induced MDR1 mRNA silencing of over 80% was achieved.

Keywords: Chondrosarcoma; MDR1; housekeeping genes; mRNA silencing; osteosarcoma; siRNA transfection reagents.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / genetics
  • Cell Line, Tumor
  • Chondrosarcoma* / drug therapy
  • Chondrosarcoma* / genetics
  • Humans
  • Osteosarcoma* / genetics
  • Osteosarcoma* / pathology
  • RNA, Small Interfering / genetics
  • Transfection

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • RNA, Small Interfering